Sanofi

Filings by Sanofi span 6 companies, the busiest being Regeneron Pharmaceuticals, Inc., Attovia Therapeutics, Inc. and Latigo Biotherapeutics, Inc. Between 12 January 2016 and 10 August 2026, the trades on record add up to 25 filings.

Purchases make up the whole of the open-market record (21 purchases, €4.4M). The totals do not cover 20 filings with an undisclosed amount. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. So far in 2026, the count stands at 1 purchase and no sales.

On 1 out of 20 purchases, another insider of the same company was buying within the same 30 days. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase.

The record was last updated on 12 August 2026 with a transaction in Latigo Biotherapeutics, Inc. The last insider purchase was made public on 7 August 2026, 72 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. Section 16 rules allow two business days to file each Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.